Company intelligence / Profile preview

Theron Pharmaceuticals

Los Altos, California, United Statestheronpharma.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Theron's lead candidate, TRN-157, is a novel long acting M3 muscarinic antagonist designed for once-daily inhaled use with broad device flexibility. It has completed Phase 1 and Phase 2a clinical trials demonstrating safety and bronchodilator activity in mild to moderate asthmatics. The company aims to address unmet needs in COPD and severe asthma by enabling combination therapies with improved convenience and outcomes.

Therapeutic areas: Pulmonology
Modalities: Small molecules (specifically long acting muscarinic antagonists, LAMAs)
Industry: Biotech

Drug pipeline

1 asset

TRN-157

Phase 1

Indications: Chronic obstructive pulmonary disease, Severe asthma

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of the latest available information.

Beyond the preview

Go deeper on Theron Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Theron Pharmaceuticals.

Explore the full profile